- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/09 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
Patent holdings for IPC class C07D 207/09
Total number of patents in this class: 489
10-year publication summary
|
35
|
36
|
33
|
48
|
38
|
31
|
33
|
34
|
40
|
33
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| LB Pharmaceuticals Inc. | 27 |
9 |
| Ligand Pharmaceuticals Incorporated | 168 |
8 |
| Sunovion Pharmaceuticals Inc. | 244 |
8 |
| Merck Sharp & Dohme Corp. | 2183 |
7 |
| Massachusetts Institute of Technology | 10259 |
7 |
| Tetraphase Pharmaceuticals, Inc. | 52 |
7 |
| Saniona A/S | 53 |
7 |
| Nocion Therapeutics, Inc. | 51 |
7 |
| Bristol-myers Squibb Company | 4747 |
6 |
| Janssen Pharmaceutica N.V. | 3160 |
6 |
| Takeda Pharmaceutical Company Limited | 2713 |
6 |
| Theravance Biopharma R&D IP, LLC | 360 |
6 |
| H. Lundbeck A/S | 1232 |
6 |
| Hoffmann-La Roche Inc. | 3804 |
5 |
| The Regents of the University of California | 20790 |
5 |
| The Trustees of the University of Pennsylvania | 4416 |
5 |
| Concentric Analgesics, Inc. | 11 |
5 |
| Ensysce Biosciences, Inc. | 24 |
5 |
| Oryzon Genomics S.A. | 103 |
5 |
| Mission Therapeutics Limited | 80 |
5 |
| Other owners | 364 |